Aktis Oncology (NASDAQ:AKTS) Trading 6.6% Higher Following Analyst Upgrade

Aktis Oncology (NASDAQ:AKTS) traded up 6.6% during trading on Tuesday after Raymond James Financial upgraded the stock to a strong-buy rating. The company traded as high as $22.12 and last traded at $22.0490. 46,609 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 297,901 shares. The stock had previously closed at $20.69.

AKTS has been the topic of a number of other reports. Weiss Ratings cut shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, June 9th. William Blair assumed coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating on the stock. Finally, HC Wainwright upped their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.

Aktis Oncology Trading Up 4.0%

The business has a 50 day moving average price of $19.54.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million for the quarter. On average, analysts predict that Aktis Oncology will post -1.62 EPS for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.